(4-hydroxy-benzo[b]thiophen-3-yl)-acetic acid ethyl ester | 726174-51-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: (4-hydroxy-benzo[b]thiophen-3-yl)-acetic acid ethyl ester
• 英文别名: ethyl 2-(4-hydroxy-1-benzothiophen-3-yl)acetate
• CAS: 726174-51-2
• 化学式: C₁₂H₁₂O₃S
• 分子量: 236.291
• InChiKey: PSCHCBLKRYUWHK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  74.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  (4-methoxy-benzo[b]thiophen-3-yl)-acetic acid ethyl ester 在 三溴化硼 作用下， 以 正庚烷 、 二氯甲烷 为溶剂， 反应 2.0h， 生成 (4-hydroxy-benzo[b]thiophen-3-yl)-acetic acid ethyl ester
  参考文献：
  名称：

  [EN] FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS
  [FR] DERIVES HETEROCYCLIQUES FUSIONNES UTILISES EN TANT QUE MODULATEURS PPAR

  摘要：

  本发明涉及由以下结构式I表示的化合物：其中（a）X选自单键、O、S、S（O）2和N组成的群；（b）U是脂肪链连接物；（c）Y选自C、O、S、NH和单键组成的群；（d）E是C（R3）（R4）A或A，其中（i）A选自羧基、四唑基、C1-C6烷基腈、羧酰胺、磺酰胺和酰基磺酰胺组成的群；（e）B选自S、O、C和N组成的群；（f）Z选自N和C组成的群；但当B为C时，则Z为N。

  公开号：

  WO2004063155A1

文献信息

• [EN] FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS<br/>[FR] DERIVES HETEROCYCLIQUES FUSIONNES UTILISES EN TANT QUE MODULATEURS PPAR
  申请人：LILLY CO ELI

  公开号：WO2004063155A1

  公开（公告）日：2004-07-29

  The present invention is directed to compounds represented by the following structural formula, Formula I: wherein (a) X is selected from the group consisting of a single bond, O, S. S(O)2 and N; (b) U is an aliphatic linker; (c) Y is selected from the group consisting of C, O, S, NH and a single bond; (d) E is C(R3) (R4)A or A and wherein (i) A is selected from the group consisting of carboxyl, tetrazole, C1-C6 alkylnitrile, carboxamidek, sulfonamide and acylsulfonamide; (e) B is selected from the group consisting of S, O, C, and N; (f) Z is selected from the group consisting of N and C; with the proviso that when B is C then Z is N.

  本发明涉及由以下结构式I表示的化合物：其中（a）X选自单键、O、S、S（O）2和N组成的群；（b）U是脂肪链连接物；（c）Y选自C、O、S、NH和单键组成的群；（d）E是C（R3）（R4）A或A，其中（i）A选自羧基、四唑基、C1-C6烷基腈、羧酰胺、磺酰胺和酰基磺酰胺组成的群；（e）B选自S、O、C和N组成的群；（f）Z选自N和C组成的群；但当B为C时，则Z为N。
• Fused heterocyclic derivates as ppar modulators
  申请人：Conner Eugene Scott

  公开号：US20060217374A1

  公开（公告）日：2006-09-28

  The present invention is directed to a method of treatment by modulating a peroxisome proliferator activated receptor by employing a compound of Structural Formula (I). The variables in I are defined herein. Also included are compounds, methods of making compounds, and pharmaceutical compositions. The compounds of the present invention are believed to be effective in treating and preventing Syndrome X, Type H diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis, and other disorders related to Syndrome X and cardiovascular diseases.

  本发明涉及一种通过利用结构式（I）的化合物来调节过氧化物酶体增殖物激活受体进行治疗的方法。I中的变量在此定义。还包括化合物、制备化合物的方法和制药组合物。本发明的化合物被认为在治疗和预防综合征X、H型糖尿病、高血糖、高脂血症、肥胖症、凝血障碍、高血压、动脉粥样硬化和其他与综合征X和心血管疾病相关的疾病方面具有疗效。
• Fused heterocyclic derivatives as PPAR modulators
  申请人：Eli Lilly and Company

  公开号：US07528160B2

  公开（公告）日：2009-05-05

  The present invention is directed to a method of treatment by modulating a peroxisome proliferator activated receptor by employing a compound of Structural Formula (I). The variables in I are defined herein. Also included are compounds, methods of making compounds, and pharmaceutical compositions. The compounds of the present invention are believed to be effective in treating and preventing Syndrome X, Type H diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis, and other disorders related to Syndrome X and cardiovascular diseases.

  本发明涉及一种通过使用结构式（I）化合物调节过氧化物酶体增殖激活受体进行治疗的方法。I中的变量在此定义。还包括化合物、制备化合物的方法和制药组合物。本发明的化合物被认为对治疗和预防综合征X、H型糖尿病、高血糖、高脂血症、肥胖症、凝血异常、高血压、动脉粥样硬化和与综合征X和心血管疾病相关的其他疾病有效。
• Fused heterocyclic derivatives as ppar modulators
  申请人：Conner Eugene Scott

  公开号：US20060205744A1

  公开（公告）日：2006-09-14

  The present invention is directed to compounds represented by the following structural formula, Formula I: wherein (a) X is selected from the group consisting of a single bond, O, S, S(O) 2 and N; (b) U is an aliphatic linker, (c) Y is selected from the group consisting of C, O, S, NH and a single bond; (d) E is C(R3) (R4) A or A and wherein (i) A is selected from the group consisting of carboxyl, tetrazole, C 1 -C 6 alkylnitrile, carboxamidek, sulfonamide and acylsulfonamide; (e) B is selected from the group consisting of S, O, C, and N; (f) Z is selected from the group consisting of N and C; with the proviso that when B is C then Z is N.

  本发明涉及由以下结构式表示的化合物，即式 I： 其中 (a) X 选自单键、O、S、S(O) 2 和 N 所组成的组；(b) U 是脂肪族连接体，(c) Y 选自 C、O、S、NH 和单键组成的组；(d) E 是 C(R3) (R4) A 或 A，其中(i) A 选自羧基、四唑、C 1 -C 6 烷基腈、羧酰胺、磺酰胺和酰基磺酰胺组成的组； (e) B 选自 S、O、C 和 N 组成的组； (f) Z 选自 N 和 C 组成的组；但当 B 为 C 时，Z 为 N。
• FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS
  申请人：ELI LILLY AND COMPANY

  公开号：EP1581521A1

  公开（公告）日：2005-10-05